<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; create</title>
	<atom:link href="http://www.tapanray.in/tag/create/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Focus More To Create Patient-Perceived Value of Brand Outcomes</title>
		<link>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=focus-more-to-create-patient-perceived-value-of-brand-outcomes</link>
		<comments>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/#comments</comments>
		<pubDate>Mon, 01 Nov 2021 00:00:27 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2021]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[affordable]]></category>
		<category><![CDATA[age]]></category>
		<category><![CDATA[brand outcomes]]></category>
		<category><![CDATA[changes]]></category>
		<category><![CDATA[channels]]></category>
		<category><![CDATA[Complex]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[criticality]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[group]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[older]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[perceived]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[services]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10603</guid>
		<description><![CDATA[Healthcare providers, including many drug companies aim to create a beneficial effect on patients with their respective products and services. However, and more importantly, these benefits need to be such that recipients are able to sense, feel, and perceive as &#8230; <a href="http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/focus-more-to-create-patient-perceived-value-of-brand-outcomes/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create Greater Patient–Value To Excel With Repurposed Covid Brands</title>
		<link>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-greater-patient-value-to-excel-with-repurposed-covid-brands</link>
		<comments>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/#comments</comments>
		<pubDate>Mon, 23 Nov 2020 00:00:11 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[antivirals]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[delivery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inhaler]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[NDDS]]></category>
		<category><![CDATA[novel]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Relevance]]></category>
		<category><![CDATA[repurposed]]></category>
		<category><![CDATA[segments]]></category>
		<category><![CDATA[small]]></category>
		<category><![CDATA[systems]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10335</guid>
		<description><![CDATA[Regular introduction of new molecules, line extensions or a Novel Drug delivery System (NDDS) has remained the life blood for pharma to rejuvenate a company’s product portfolio for driving organizational growth. But, Covid’s unprecedented and devastating assault on human lives &#8230; <a href="http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-greater-patient-value-to-excel-with-repurposed-covid-brands/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Could M&amp;As in Pharma create significant stakeholder value?</title>
		<link>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=could-mas-in-pharma-create-significant-stakeholder-value</link>
		<comments>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/#comments</comments>
		<pubDate>Mon, 25 Apr 2011 01:00:33 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[acquisitions]]></category>
		<category><![CDATA[consolidation]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[in]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[M&A]]></category>
		<category><![CDATA[mergers]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Players]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[significant]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[valuation]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=269</guid>
		<description><![CDATA[At the very outset, I pay my homage to the departed soul of our industry colleague respected Amar Lulla, former joint managing director of Cipla, who passed away on Friday, April 22, 2011 after a prolonged battle against cancer. As &#8230; <a href="http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/could-mas-in-pharma-create-significant-stakeholder-value/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Create, Deliver and Realize maximum value from a new product launch with an innovative Supply Chain Management system</title>
		<link>http://www.tapanray.in/create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system</link>
		<comments>http://www.tapanray.in/create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system/#comments</comments>
		<pubDate>Mon, 30 Aug 2010 01:00:49 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[a]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[deliver]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Heparin]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[launch]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[maximum]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Realize]]></category>
		<category><![CDATA[SCS]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[with]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=381</guid>
		<description><![CDATA[Like in many other industries, effective supply-chain management (SCM) in the pharmaceutical industry involves a systematic process, spanning from procurement of raw, packaging and other related materials, converting those materials into finished goods stock keeping units (SKUs), inventory management of &#8230; <a href="http://www.tapanray.in/create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/create-deliver-and-realize-maximum-value-from-a-new-product-launch-with-an-innovative-supply-chain-management-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>‘Swine Flu’ – why create so much of scare to disturb public life?</title>
		<link>http://www.tapanray.in/swine-flu-why-create-so-much-of-scare-to-disturb-public-life/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=swine-flu-why-create-so-much-of-scare-to-disturb-public-life</link>
		<comments>http://www.tapanray.in/swine-flu-why-create-so-much-of-scare-to-disturb-public-life/#comments</comments>
		<pubDate>Thu, 13 Aug 2009 01:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[create]]></category>
		<category><![CDATA[disturb]]></category>
		<category><![CDATA[Flu]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[much]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scare]]></category>
		<category><![CDATA[so]]></category>
		<category><![CDATA[Swine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[why]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=809</guid>
		<description><![CDATA[Why has so much of scare been created on ‘Swine Flu’ in India? Who are responsible for creating and spreading such panic?Any attempted answers to these question perhaps will remain baffling to many of us when we read that out &#8230; <a href="http://www.tapanray.in/swine-flu-why-create-so-much-of-scare-to-disturb-public-life/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/swine-flu-why-create-so-much-of-scare-to-disturb-public-life/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
